BioStock: Elicera Therapeutics enters first international collaboration involving iTANK

Swedish biotech Elicera Therapeutics has signed a Material Transfer Agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain. The agreement allows the institute’s CAR T-cells to be armed with Elicera’s iTANK platform as they research treatments for Ewing Sarcoma, a solid tumour that currently has limited treatment options. BioStock got in touch with Elicera’s CEO Jamal El-Mosleh to learn more about the news.

Read the full interview with Elicera’s CEO Jamal El-Mosleh at biostock.se:

Elicera Therapeutics enters first international collaboration involving iTANK - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/